Free Trial

Pacific Point Advisors LLC Buys Shares of 1,000 Axon Enterprise, Inc (NASDAQ:AXON)

Axon Enterprise logo with Aerospace background

Pacific Point Advisors LLC acquired a new position in shares of Axon Enterprise, Inc (NASDAQ:AXON - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,000 shares of the biotechnology company's stock, valued at approximately $526,000.

Several other large investors also recently made changes to their positions in the stock. Fourth Dimension Wealth LLC acquired a new position in Axon Enterprise during the fourth quarter worth $30,000. Bartlett & CO. Wealth Management LLC boosted its holdings in Axon Enterprise by 132.0% during the first quarter. Bartlett & CO. Wealth Management LLC now owns 58 shares of the biotechnology company's stock worth $31,000 after purchasing an additional 33 shares during the last quarter. Catalyst Capital Advisors LLC acquired a new position in Axon Enterprise during the first quarter worth $32,000. Alpine Bank Wealth Management acquired a new position in Axon Enterprise during the first quarter worth $40,000. Finally, Elequin Capital LP acquired a new position in Axon Enterprise during the fourth quarter worth $46,000. Institutional investors own 79.08% of the company's stock.

Axon Enterprise Stock Performance

Shares of AXON traded down $11.94 during trading hours on Tuesday, hitting $790.22. The company had a trading volume of 507,731 shares, compared to its average volume of 513,715. The firm has a market cap of $61.52 billion, a price-to-earnings ratio of 492.12, a PEG ratio of 92.34 and a beta of 1.29. The business has a fifty day moving average of $740.97 and a 200-day moving average of $637.30. Axon Enterprise, Inc has a 12 month low of $279.02 and a 12 month high of $830.21. The company has a quick ratio of 2.62, a current ratio of 2.83 and a debt-to-equity ratio of 0.68.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.07. The company had revenue of $603.63 million for the quarter, compared to analyst estimates of $585.67 million. Axon Enterprise had a net margin of 14.86% and a return on equity of 5.81%. The company's revenue was up 31.3% on a year-over-year basis. During the same period in the prior year, the firm earned $1.15 earnings per share. Equities analysts anticipate that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Insider Buying and Selling at Axon Enterprise

In related news, CEO Patrick W. Smith sold 10,000 shares of the firm's stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $540.99, for a total transaction of $5,409,900.00. Following the transaction, the chief executive officer directly owned 3,063,982 shares of the company's stock, valued at approximately $1,657,583,622.18. This trade represents a 0.33% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Michael Garnreiter sold 5,913 shares of the firm's stock in a transaction dated Wednesday, June 4th. The stock was sold at an average price of $760.00, for a total transaction of $4,493,880.00. Following the transaction, the director directly owned 17,740 shares in the company, valued at approximately $13,482,400. This represents a 25.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 44,642 shares of company stock valued at $30,500,428 in the last quarter. Company insiders own 5.70% of the company's stock.

Wall Street Analysts Forecast Growth

AXON has been the subject of a number of recent analyst reports. Barclays increased their price target on shares of Axon Enterprise from $726.00 to $735.00 and gave the company an "overweight" rating in a research note on Friday, May 9th. Craig Hallum cut shares of Axon Enterprise from a "buy" rating to a "cautious" rating in a research note on Monday, March 10th. Needham & Company LLC increased their price target on shares of Axon Enterprise from $600.00 to $750.00 and gave the company a "buy" rating in a research note on Thursday, May 8th. Bank of America increased their price target on shares of Axon Enterprise from $750.00 to $895.00 and gave the company a "buy" rating in a research note on Wednesday, June 4th. Finally, Wolfe Research initiated coverage on shares of Axon Enterprise in a research note on Monday. They issued an "outperform" rating for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $699.55.

Check Out Our Latest Analysis on AXON

About Axon Enterprise

(Free Report)

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.

See Also

Institutional Ownership by Quarter for Axon Enterprise (NASDAQ:AXON)

Should You Invest $1,000 in Axon Enterprise Right Now?

Before you consider Axon Enterprise, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axon Enterprise wasn't on the list.

While Axon Enterprise currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Made in America Stocks Under $20 You Need to See!
3 Cheap Growth Stocks Set to Explode This Summer
The Next NVIDIA? Quantum Computing Stocks Set for Explosive Growth

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines